IntegraGen

Equities

ALINT

FR0010908723

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:37:11 2024-04-29 am EDT			5-day change	1st Jan Change
0.6 ^EUR	+1.69%		0.00%	-32.89%

2023	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	IntegraGen SA Announces Revenue Results for the First Half of 2023	CI

Integragen Sa Reports Earnings Results for the Full Year Ended December 31, 2020

April 19, 2021 at 11:18 pm EDT

IntegraGen SA announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was EUR 9.146 million compared to EUR 8.322 million a year ago. Operating loss was EUR 254,138 compared to EUR 363,065 a year ago. Net loss was EUR 375,021 compared to EUR 284,839 a year ago.

Latest news about IntegraGen

IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-23	CI
IntegraGen SA Announces Revenue Results for the First Half of 2023	23-07-13	CI
IntegraGen Announces Unaudited Revenue Results for the Full Year 2022	23-01-13	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-18	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended September 30, 2022	22-10-18	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended September 30, 2022	22-10-18	CI
IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
IntegraGen SA Announces Earnings Result for the First Half of 2021	21-10-08	CI
Global markets live: Intel, Moderna, Burberry, Pfizer, SoftwareOne, Swisscom...	21-07-16
IntegraGen SA Announces Unaudited Turnover for the First Half of 2021	21-07-16	CI
Integragen Sa Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-19	CI
OncoDNA SA completed the acquisition of 64.7% stake in IntegraGen SA for €9.4 million.	20-11-11	CI
Integragen Sa Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-17	CI
IntegraGen Announces Unaudited Sales for the First Half of 2020	20-07-09	CI
OncoDNA SA signed an agreement to acquire IntegraGen SA for €14.5 million.	20-07-08	CI
U.S. Cancer Center to Use IntegraGen's MERCURY™ Cloud-Based Tool for Oncology Sequencing Data Interpretation and Reporting	20-03-26	CI
IntegraGen SA Announces Financial Results for the Half Year Ended June 30, 2018	18-09-19	CI
IntegraGen SA Announces Results of the Ability of miR-31-3p to Predict Response to Therapy for Patients with Metastatic Colorectal Cancer	18-09-04	CI
The SeqOIA Cooperative Health Group Selects Integragen as the Operator of its Sequencing Platform as Part of the France Genomic Medicine 2025 Plan	18-07-31	CI
IntegraGen SA Announces Earnings Results for the Year Ended Dec. 31, 2017; Provides Revenue Guidance for 2018	18-04-12	CI
IntegraGen Presents Positive Data from Liquid Biopsy Studies of Company’s Proprietary miRNAs during 2018 European Lung Cancer Conference	18-04-12	CI
IntegraGen SA Announces Global Distribution Agreement with Twist Bioscience Corp	18-02-14	CI
IntegraGen and GoPath Laboratories Sign Licensing Agreement for the Commercialization of Mir-31-3P Test in North America	18-01-09	CI
Integragen Sa Announces Results from an Analysis of miR-31-3p Expression in Tumor Samples from Patients Enrolled in the NEW EPOC Clinical Trial	17-10-09	CI
IntegraGen SA Announces Financial Results for the Half Year Ended June 30, 2017	17-09-28	CI

Chart IntegraGen

Duration

Period

More charts

Company Profile

IntegraGen specializes in researching and identifying genetic biomarkers and in developing and marketing molecular diagnostic products and services, primarily in the field of oncology. The group's activity is organized around two sectors: - supply of genomic research services: high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups; - sales of diagnostic solutions. France accounts for 88% of net sales.

Sector

Biotechnology & Medical Research

Calendar

2024-10-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
INTEGRAGEN	-32.89%	4.18M
EXACT SCIENCES CORPORATION	-20.00%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+47.79%	3.25B
GUARDANT HEALTH, INC.	-33.11%	2.11B
BGI GENOMICS CO., LTD.	-14.15%	2.08B
VERACYTE, INC.	-25.55%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+19.31%	1.02B
SEEGENE, INC.	-2.62%	733M
CAREDX, INC	-30.75%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-43.98%	383M

Bio Diagnostics & Testing